You are here: Home >
Staff > Ms Beatriz Alvarez Rodriguez
Contact: Garstang 8.61,
Álvarez-Rodríguez B, Latorre A, Posch C, Somoza Á Recent advances in uveal melanoma treatment Medicinal Research Reviews 37 1350-1372, 2017DOI:10.1002/med.21460View abstract
© 2017 Wiley Periodicals, Inc. Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Recent advances in the understanding of molecular characteristics helped to determine which tumors are most likely to progress. About 50% of patients carrying genetic alterations such aschromosomal aberrations and mutations are at significant risk for metastatic disease of which the majority will succumb to UM within few months. Currently, there is no effective treatment for metastatic uveal melanoma, and we hope this review will encourage researchers and clinicians to work to finda better standard of care. In this article we provide a comprehensive overview of the molecular framework of UM, highlighting the most common mutations involved in this kind of cancer. It also covers the most recent treatments from basic research to clinical trials, including small molecules, nucleic acids or immunotherapy, among others. It is intended to serve as a key reference for clinicians and researchers working in this field.